** Shares of Innovent Biologics 1801.HK climb 3.2% to HK$36.65, on track for the biggest one-day pct rise since Dec. 9
** Innovent Biologics says China's National Medical Products Administration (NMPA) has approved second New Drug Application (NDA) of DOVBLERON, which is an oral ROS1 inhibitor for treatment of adult patients with metastatic ROS1-positive non-small cell lung cancer
** Says the NDA was accepted by the U.S. Food and Drug Administration for priority review in December 2024
** Hang Seng Commerce & Industry Index .HSNC and healthcare index .HSCIH both gain 0.4% while Hang Seng Index .HSI adds 0.2%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。